title: The role of progestogens in regulating matrix metalloproteinase activity in macrophages and microglial cells.
abstract: Although the systemic effects of progestogens have been extensively studied, little is known in regards to the cellular effects of these compounds. Using a cellular model for vascular (macrophages) and brain (microglial) cells, we studied the effects of various progestogens, either alone or in combination with 17β-estradiol (E(2)) on the activity of matrix metalloproteinase-9 (MMP-9), a proteolytic enzyme involved in vascular remodeling and plaque destabilization in cardiovascular events, blood-brain barrier breakdown in stroke and brain regeneration and neurovascular remodeling during repair phases of brain injury. In the absence of E(2), medroxyprogesterone acetate (MPA), a synthetic progestogen and progesterone (PG) metabolites tended to increase MMP-9 enzyme activity in macrophages and microglial cells, whereas PG decreased such activity in macrophages; exceptions being that MPA and the PG metabolite, pregnanediol (Pdiol) had no effect on macrophage MMP-9 enzyme activity and PG had no effect on microglial cell MMP-9 enzyme activity. In the presence of E(2), an opposite affect was observed whereby MPA and the PG metabolites tended to decrease MMP-9 enzyme activity from macrophages and microglial cells, whereas PG had no effect; exceptions being that MPA and Pdiol had no effect on macrophage MMP-9 enzyme activity. In conclusion, these results demonstrate that the effects of PG, PG metabolites and MPA on MMP-9 enzyme activity differ across vascular and brain cells when administered alone or in combination with E(2) which could have important mechanistic implications for hormone therapy.
authors: Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Ave, PSC 612, Los Angeles, CA 90033, USA. julianah@usc.edu
authors: Juliana
authors: J
authors: Hwang-Levine
authors: Frank Z
authors: FZ
authors: Stanczyk
authors: Howard N
authors: HN
authors: Hodis
references: Menopause. 2002 Jul-Aug;9(4):273-81
references: 12082363
references: J Clin Endocrinol Metab. 2002 May;87(5):2346-51
references: 11994386
references: Reprod Domest Anim. 2011 Apr;46(2):197-204
references: 20477983
references: Neurochem Int. 2003 Aug;43(3):191-6
references: 12689599
references: Intern Emerg Med. 2010 Feb;5(1):13-25
references: 19626421
references: Endocrinology. 2002 Jan;143(1):205-12
references: 11751611
references: Neuropharmacology. 2008 Aug;55(2):127-38
references: 18572204
references: Climacteric. 2002 Sep;5(3):229-35
references: 12419080
references: Biochim Biophys Acta. 1998 Mar 5;1406(2):169-74
references: 9573355
references: Am J Physiol Endocrinol Metab. 2003 Dec;285(6):E1237-45
references: 12915398
references: JAMA. 1995 Jan 18;273(3):199-208
references: 7807658
references: Atherosclerosis. 2006 Nov;189(1):76-82
references: 16386257
references: J Neuropathol Exp Neurol. 2009 Dec;68(12):1309-18
references: 19915485
references: CNS Neurol Disord Drug Targets. 2008 Jun;7(3):243-53
references: 18673209
references: Rheumatol Int. 2003 Nov;23(6):282-8
references: 12684836
references: Contraception. 1990 Apr;41(4):399-410
references: 2335104
references: Curr Alzheimer Res. 2008 Apr;5(2):212-24
references: 18393806
references: Mol Cell Biol. 2003 Mar;23(5):1633-46
references: 12588983
references: Breast Cancer Res Treat. 2003 Mar;78(2):167-78
references: 12725417
references: J Neurosci. 2005 May 11;25(19):4706-18
references: 15888646
references: Endocrine. 2006 Apr;29(2):271-4
references: 16785602